Bank of Nova Scotia’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$113M Buy
181,706
+84,186
+86% +$57.3M 0.17% 97
2026
Q1
$75.3M Sell
97,520
-22,491
-19% -$17.2M 0.13% 134
2025
Q4
$92.6M Sell
120,011
-158,540
-57% -$108M 0.14% 126
2025
Q3
$157M Buy
278,551
+29,273
+12% +$16.6M 0.28% 63
2025
Q2
$131M Buy
249,278
+126,689
+103% +$70.7M 0.27% 63
2025
Q1
$77.7M Buy
122,589
+32,427
+36% +$22.3M 0.17% 103
2024
Q4
$64.2M Sell
90,162
-8,529
-9% -$7.16M 0.11% 142
2024
Q3
$104M Buy
98,691
+2,555
+3% +$2.84M 0.21% 80
2024
Q2
$101M Buy
96,136
+70,928
+281% +$68.8M 0.2% 80
2024
Q1
$24.3M Sell
25,208
-1,940
-7% -$1.84M 0.05% 239
2023
Q4
$23.8M Sell
27,148
-24,320
-47% -$20M 0.04% 268
2023
Q3
$42.4M Buy
51,468
+25,722
+100% +$20.2M 0.11% 153
2023
Q2
$18.5M Buy
25,746
+18,055
+235% +$13.9M 0.05% 216
2023
Q1
$6.32M Sell
7,691
-7,158
-48% -$5.4M 0.02% 347
2022
Q4
$10.7M Sell
14,849
-12,993
-47% -$9.59M 0.03% 339
2022
Q3
$19.2M Sell
27,842
-12,922
-32% -$8.13M 0.06% 228
2022
Q2
$24.1M Buy
40,764
+25,994
+176% +$16.9M 0.06% 250
2022
Q1
$10.3M Sell
14,770
-39,335
-73% -$24.9M 0.02% 444
2021
Q4
$34.2M Sell
54,105
-69,070
-56% -$42.5M 0.05% 295
2021
Q3
$74.5M Sell
123,175
-22,473
-15% -$14M 0.13% 153
2021
Q2
$81.4M Buy
145,648
+125,015
+606% +$63.3M 0.15% 129
2021
Q1
$9.76M Buy
20,633
+1,914
+10% +$932K 0.02% 409
2020
Q4
$9.04M Sell
18,719
-39,575
-68% -$21.4M 0.02% 388
2020
Q3
$32.6M Buy
58,294
+45,042
+340% +$27.3M 0.09% 197
2020
Q2
$8.26M Sell
13,252
-51,894
-80% -$29.5M 0.03% 329
2020
Q1
$31.8M Sell
65,146
-25,726
-28% -$10.6M 0.11% 168
2019
Q4
$34.1M Sell
90,872
-31,241
-26% -$10.5M 0.08% 202
2019
Q3
$33.9M Buy
122,113
+100,281
+459% +$29.7M 0.1% 183
2019
Q2
$6.83M Buy
21,832
+4,420
+25% +$1.47M 0.03% 356
2019
Q1
$7.15M Buy
17,412
+791
+5% +$326K 0.03% 364
2018
Q4
$6.21M Buy
16,621
+853
+5% +$312K 0.03% 360
2018
Q3
$6.37M Sell
15,768
-4,797
-23% -$1.83M 0.03% 384
2018
Q2
$7.09M Buy
20,565
+10,750
+110% +$3.36M 0.04% 300
2018
Q1
$3.38M Sell
9,815
-15,438
-61% -$5.37M 0.02% 456
2017
Q4
$9.49M Buy
25,253
+11,909
+89% +$4.82M 0.04% 322
2017
Q3
$5.97M Sell
13,344
-3,843
-22% -$1.83M 0.03% 341
2017
Q2
$8.44M Sell
17,187
-230
-1% -$101K 0.04% 321
2017
Q1
$6.75M Buy
17,417
+13,003
+295% +$4.82M 0.03% 349
2016
Q4
$1.62M Buy
4,414
+2,829
+178% +$1.08M 0.01% 416
2016
Q3
$637K Sell
1,585
-40,358
-96% -$16.2M ﹤0.01% 475
2016
Q2
$14.6M Buy
41,943
+40,478
+2,763% +$15.6M 0.09% 119
2016
Q1
$528K Buy
1,465
+20
+1% +$8.24K ﹤0.01% 465
2015
Q4
$784K Buy
1,445
+8
+0.6% +$4.33K ﹤0.01% 427
2015
Q3
$668K Buy
1,437
+117
+9% +$62.8K ﹤0.01% 373
2015
Q2
$673K Buy
1,320
+61
+5% +$29.8K ﹤0.01% 322
2015
Q1
$568K Sell
1,259
-81
-6% -$34.3K ﹤0.01% 341
2014
Q4
$550K Sell
1,340
-17
-1% -$6.68K ﹤0.01% 346
2014
Q3
$489K Buy
1,357
+100
+8% +$33.5K ﹤0.01% 366
2014
Q2
$355K Buy
1,257
+125
+11% +$37K ﹤0.01% 414
2014
Q1
$340K Buy
1,132
+18
+2% +$5.55K ﹤0.01% 437
2013
Q4
$307K Buy
1,114
+171
+18% +$49.2K ﹤0.01% 459
2013
Q3
$295K Sell
943
-168
-15% -$44.2K ﹤0.01% 417
2013
Q2
$250K Buy
+1,111
New +$259K ﹤0.01% 425

Other funds holding REGN

Bank of Nova Scotia's REGN Position: Q2 2026 in Review

Bank of Nova Scotia increased its Regeneron Pharmaceuticals (REGN) stake by 86% in Q2 2026, buying an estimated $57.3M and bringing the position to 181,706 shares worth $113M. The position accounts for 0.17% of the portfolio, ranked #97.

Bank of Nova Scotia first reported a position in REGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $157M in Q3 2025. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Bank of Nova Scotia held 181,706 shares of Regeneron Pharmaceuticals worth $113M as of Q2 2026.
  • Bank of Nova Scotia bought 84,186 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $57.3M.
  • Regeneron Pharmaceuticals made up 0.17% of Bank of Nova Scotia's portfolio in Q2 2026, its #97 holding.
  • Bank of Nova Scotia first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Bank of Nova Scotia's Regeneron Pharmaceuticals position peaked at $157M in Q3 2025.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Bank of Nova Scotia's 13F filing for Q2 2026, filed 12 Aug 2026.